Proscia And Nucleai Partner To Broaden Access To AI Predictive Biomarkers
June 25, 2024 08:00 ET
|
Proscia
PHILADELPHIA and CHICAGO, June 25, 2024 (GLOBE NEWSWIRE) -- Proscia®, a global leader in AI-enabled pathology solutions for precision medicine, has partnered with Nucleai, a leading spatial AI...
Global Tissue Diagnostics Market Size To Worth USD 10.8 Billion By 2033 | CAGR of 8.22%
June 24, 2024 20:00 ET
|
SPHERICAL INSIGHTS LLP
New York, United States , June 24, 2024 (GLOBE NEWSWIRE) -- The Global Tissue Diagnostics Market Size is to Grow from USD 4.9 Billion in 2023 to USD 10.8 Billion by 2033, at a Compound Annual Growth...
Global Biomarker Clinical Phase Outsourcing Services Market Size To Exceed USD 46.5 Billion By 2033 l CAGR of 20.02%
June 20, 2024 22:00 ET
|
SPHERICAL INSIGHTS LLP
New York, United States , June 20, 2024 (GLOBE NEWSWIRE) -- The Global Biomarker Clinical Phase Outsourcing Services Market Size is to Grow from USD 7.5 Billion in 2023 to USD 46.5 Billion by 2033,...
Companion Diagnostics Market Anticipated To Grow At 12.5% CAGR, Reaching USD 26.0 Billion By 2033 | Dimension Market Research
June 10, 2024 10:24 ET
|
Dimension Market Research
New York, June 10, 2024 (GLOBE NEWSWIRE) -- Market Overview The Global Companion Diagnostics Market size is expected to reach USD 9.0 billion by 2024 and is further anticipated to reach USD...
Cyclacel’s Fadraciclib Demonstrates Efficacy in Patient-Derived Colorectal Cancer Models at the 2024 ASCO Annual Meeting
June 04, 2024 08:00 ET
|
Cyclacel
- Novel CDK2/9 inhibitor fadraciclib induces anaphase catastrophe, a novel cancer-specific mechanism of action - BERKELEY HEIGHTS, N.J., June 04, 2024 (GLOBE NEWSWIRE) --...
At ASCO 2024, Treos Bio Reports Key Survival Results for Chemo-Free Regimen of PolyPEPI1018 Peptide Immunotherapy and Roche’s PD-L1 Inhibitor in Late-Stage Colorectal Cancer
June 03, 2024 07:00 ET
|
Treos Bio Corp.
Treos Bio reports promising survival results for chemo-free PolyPEPI1018 cancer vaccine combined with Roche's PD-L1 inhibitor in MSS mCRC at 2024 ASCO
Precede Biosciences Presents New Data at ASCO 2024 Demonstrating Accurate HER2 Status Detection Across Multiple Cancers and the Ability to Quantify ER Pathway Activation in Breast Cancer from a Simple Blood Test
June 02, 2024 10:00 ET
|
Precede Biosciences, Inc.
HER2 status was accurately assessed in 172 patients with advanced breast, gastroesophageal, and ovarian cancersER status was accurately assessed and the level of ER pathway activation quantified in 87...
Asia-Pacific Genomic Cancer Panel and Profiling Market Research 2023-2024 & 2033: Advancements in Genomic Research and Increasing Focus on Precision Medicine Within Oncology
May 30, 2024 06:39 ET
|
Research and Markets
Dublin, May 30, 2024 (GLOBE NEWSWIRE) -- The "Asia-Pacific Genomic Cancer Panel and Profiling Market: Focus on Application, End User, and Country - Analysis and Forecast, 2023-2033" report has been...
Global Gene Editing Tools Market Report 2024: A $3.83 Billion Market by 2034, with a CAGR of 18.84% During 2024-2034
May 27, 2024 04:13 ET
|
Research and Markets
Dublin, May 27, 2024 (GLOBE NEWSWIRE) -- The "Global Gene Editing Tools Market" report has been added to ResearchAndMarkets.com's offering.The global gene editing tools market accounted for USD...
Global Personalized Medicine Market Research Report 2024-2032 Featuring Abbott Laboratories, GE Healthcare, Aadi Bioscience, Illumina, QIAGEN, Eli Lilly and Co, Takeda, AbbVie, F. Hoffmann-La Roche
May 24, 2024 07:39 ET
|
Research and Markets
Dublin, May 24, 2024 (GLOBE NEWSWIRE) -- The "Global Personalized Medicine Market Report by Product, Application, End-Users, Region and Company Analysis 2024-2032" report has been added to ...